MedTrace Logo

Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer

NCT04109729 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2026-03-02

No results posted yet for this study

Summary

This is a phase 1, open label, prospective, non-randomized single arm study combining Radium-223 with nivolumab in men with metastatic castration resistant prostate cancer.

Conditions

Interventions

DRUG

Nivolumab

Nivolumab 480mg IV every 4 weeks for up to 2 years

DRUG

Radium-223

Radium-223 55 kilobecquerel (kBq)/kg IV q4 weeks for 6 cycles total

Sponsors & Collaborators

Principal Investigators

  • Umang Swami, MD · Huntsman Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-16
Primary Completion
2025-02-18
Completion
2026-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04109729 on ClinicalTrials.gov